EIF2AK3 and adrenal cortex carcinoma: In agreement with previous findings, besides decreased EGFR protein levels, EGF-induced EGFR activation was abrogated by nimotuzumab treatment in ACC-M and ACC-2 cell lines, resulting in pERK down-regulation [18].